

Slc17a5 Cas9-CKO Strategy

Designer:Xueting Zhang

Reviewer: Yanhua Shen

Date:2020-02-11

Project Overview



Project Name

Slc17a5

Project type

Cas9-CKO


Strain background

C57BL/6JGpt

Conditional Knockout strategy



This model will use CRISPR/Cas9 technology to edit the Slc17a5 gene. The schematic diagram is as follows:



Technical routes



- The Slc17a5 gene has 3 transcripts. According to the structure of Slc17a5 gene, exon2-exon3 of Slc17a5-201 (ENSMUST00000052441.11) transcript is recommended as the knockout region. The region contains 431bp coding sequence. Knock out the region will result in disruption of protein function.
- ➤ In this project we use CRISPR/Cas9 technology to modify *Slc17a5* gene. The brief process is as follows:CRISPR/Cas9 system and Donor were microinjected into the fertilized eggs of C57BL/6JGpt mice. Fertilized eggs were transplanted to obtain positive F0 mice which were confirmed by PCR and sequencing. A stable F1 generation mouse model was obtained by mating positive F0 generation mice with C57BL/6JGpt mice.
- The flox mice will be knocked out after mating with mice expressing Cre recombinase, resulting in the loss of function of the target gene in specific tissues and cell types.

Notice



- ➤ According to the existing MGI data, Homozygous mutant mice exhibit numerous neurological abnormalities, including impaired exploratory and locomotor activity, hearing deficits, and an increased depressive-like response.
- The Slc17a5 gene is located on the Chr9. If the knockout mice are crossed with other mice strains to obtain double gene positive homozygous mouse offspring, please avoid the two genes on the same chromosome.
- This Strategy is designed based on genetic information in existing databases. Due to the complexity of biological processes, all risk of loxp insertion on gene transcription, RNA splicing and protein translation cannot be predicted at existing technological level.

Gene information (NCBI)



Slc17a5 solute carrier family 17 (anion/sugar transporter), member 5 [Mus musculus (house mouse)]

Gene ID: 235504, updated on 10-Oct-2019

Summary

Official Symbol Slc17a5 provided by MGI

Official Full Name solute carrier family 17 (anion/sugar transporter), member 5 provided by MGI

Primary source MGI:MGI:1924105

See related Ensembl: ENSMUSG00000049624

Gene type protein coding
RefSeq status VALIDATED
Organism Mus musculus

Lineage Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha;

Muroidea; Muridae; Murinae; Mus; Mus

Also known as SD; AST; NSD; SLD; ISSD; SIASD; SIALIN; 4732491M05; 4631416G20Rik

Expression Ubiquitous expression in kidney adult (RPKM 12.0), genital fat pad adult (RPKM 7.5) and 28 other tissues See more

Orthologs human all

Genomic context

☆ ?

Location: 9; 9 E1

See Slc17a5 in Genome Data Viewer

Exon count: 12

Annotation release	Status	Assembly	Chr	Location	
108	current	GRCm38.p6 (GCF_000001635.26)	9	NC_000075.6 (7853648778588045, complement)	
Build 37.2	previous assembly	MGSCv37 (GCF_000001635.18)	9	NC_000075.5 (7838431678435834, complement)	


Transcript information (Ensembl)



The gene has 3 transcripts, all transcripts are shown below:


Name	Transcript ID	bp	Protein	Biotype	CCDS	UniProt	Flags
SIc17a5-201	ENSMUST00000052441.11	3236	<u>495aa</u>	Protein coding	CCDS23364	Q8BN82	TSL:1 GENCODE basic APPRIS P3
SIc17a5-202	ENSMUST00000117645.7	3114	<u>469aa</u>	Protein coding	CCDS72283	Q8BN82	TSL:1 GENCODE basic APPRIS ALT2
SIc17a5-203	ENSMUST00000119213.2	1151	No protein	IncRNA	1/4/	20	TSL:1

The strategy is based on the design of Slc17a5-201 transcript, The transcription is shown below




Genomic location distribution






Protein domain





Mouse phenotype description(MGI)





Phenotypes affected by the gene are marked in blue.Data quoted from MGI database(http://www.informatics.jax.org/).

According to the existing MGI data, Homozygous mutant mice exhibit numerous neurological abnormalities, including impaired exploratory and locomotor activity, hearing deficits, and an increased depressive-like response.



If you have any questions, you are welcome to inquire. Tel: 400-9660890





